Cargando…

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Weiwei, Chen, Ziyi, Zhang, Wenling, Cheng, Ye, Zhang, Betty, Wu, Fan, Wang, Qian, Wang, Shouju, Rong, Dawei, Reiter, F. P., De Toni, E. N., Wang, Xuehao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292831/ https://www.ncbi.nlm.nih.gov/pubmed/32532960 http://dx.doi.org/10.1038/s41392-020-0187-x

Ejemplares similares

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities
por: Lu, Chen, et al.
Publicado: (2019)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Single-cell RNA sequencing of immune cells in gastric cancer patients
por: Fu, Kai, et al.
Publicado: (2020)

Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
por: Afifi, Ahmed M, et al.
Publicado: (2019)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ
por: Hao, Xiaopei, et al.
Publicado: (2022)

Clinical significance of CD8(+) T cell immunoreceptor with Ig and ITIM domains(+) in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy
por: Tang, Weiwei, et al.
Publicado: (2019)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
por: Zheng, Ruiqi, et al.
Publicado: (2023)

Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids
por: Wang, Siqi, et al.
Publicado: (2020)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma
por: Li, Xiaoju, et al.
Publicado: (2022)

Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
por: Zhang, Xinning, et al.
Publicado: (2022)

Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma
por: Wang, Huancheng, et al.
Publicado: (2020)

Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023)

Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers
por: Rong, Dawei, et al.
Publicado: (2021)

Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
por: Sun, Hong, et al.
Publicado: (2022)

The Theoretical Basis of Electrocardiology
por: Batsford, William P.
Publicado: (1978)

Summary and theoretical basis
por: Reya, E, et al.
Publicado: (1990)

Comment on “Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Qian, Xinye
Publicado: (2023)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
por: Wan, Zhong, et al.
Publicado: (2020)

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
por: Zhang, Qiang-Bo, et al.
Publicado: (2013)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Atwa, Sara M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e8j038cbbqtgtfc5ug30sk44k1